XML 96 R46.htm IDEA: XBRL DOCUMENT v3.24.1
CORPORATE INFORMATION (Tables)
 12 Months Ended
Dec. 31, 2023
Disclosure of subsidiaries [abstract]  
Information About Subsidiaries
Information about subsidiaries
CompanyPlace and date
of
incorporation		Issued ordinary
shares/paid-up
capital		Percentage of equity
interest attributable
to the Company		Principal
activities
Direct %Indirect %
Legend Biotech Limited (“Legend BVI”)The British Virgin Islands June 2, 2015US$2,453,819,239 100 — Investment holding
Legend Biotech HK Limited (“Legend HK”)Hong Kong June 3, 2015US$2,453,819,239 — 100 Investment holding
Nanjing Legend Biotechnology Co., Ltd. (“Legend Nanjing”)PRC* November 17, 2014US$212,500,000 — 100 Manufacture and sale of life sciences research products; performance and sale of research and development services
Legend Biotech USA Incorporated (“Legend USA”)Delaware, United States of America August 31, 2017— — 100 Manufacture and sale of life sciences products; performance of life sciences research and development
Legend Biotech Ireland Limited (“Legend Ireland”)Ireland November 13, 2017US$2,217,445,234 — 100 Manufacture and sale of life sciences products; performance of life sciences research and development; treasury center for Legend Biotech
Legend Biotech Belgium B.V. (“Legend Belgium”)Belgium June 23, 2021US$46,177,685 — 100 Manufacture and sale of life sciences products
Hainan Chuanji Biotechnology Co., Ltd. (“Hainan Chuanji”)PRC October 25, 2021— — 100 General & administrative
** The People’s Republic of China (the “PRC” or “China”), including the Hong Kong Special Administrative Region of China (“Hong Kong”).